Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N8: Multimodality Therapy with 3F8 for Neuroblastoma
NCT00040872Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2000
- Primary completion
- Jan 2007
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anti-GD2 monoclonal antibody 3F8 in neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Jun 2000; status: completed.
02
Drugs
anti-GD2 monoclonal antibody 3F8
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00040872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040872.